Clinical Trial Update: Refractory Chronic Cough Improvement Via NAL ER (RIVER) [Phase 2]

View source ↗

Summary

Phase 2 trial of nalbuphine ER (Haduvio) for refractory chronic cough has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Haduvio (nalbuphine extended-release)

Snippet

Sponsor: Trevi Therapeutics | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED | Results posted: 2026-03-30